Open to patients, researchers and clinicians interested in Bicuspid Aortic Valve.

Free admission.

---

Join us at the forefront of Bicuspid Aortic Valve (BAV) treatment innovation, where we're redefining the approach to aortopathy in BAV patients. With BAV affecting up to 2% of the global population and leading to serious complications like aortic aneurysms, the need for a shift towards personalised, less invasive treatments is clear.

This event is a crucial step in that direction, bringing together experts, patients, and stakeholders to explore the latest findings, including groundbreaking research from the University of Liverpool that suggests many BAV patients have structurally sound aortas, potentially changing the game in surgical intervention.

Our focused sessions will dive into all aspects of BAV aortopathy, from patient and surgeon perspectives to the latest on surveillance, family screening, and surgical guidelines. We're on a mission to enhance patient quality of life, reduce unnecessary surgeries, and pave the way for early diagnosis and tailored treatments.

Be part of this transformative journey. Your insights and participation are key to setting new standards of care by 2028, where individual needs guide BAV treatment, ensuring better outcomes and minimised risks.

---

Speakers to be announced soon. Programme to cover:

• The Patient's Perspective
• The Surgeon's Perspective 
• Congenital Defect vs Haemodynamics
• Is BAV protective for Type A Dissection and Thoracic Aortic Aneurysm Rupture? 
• BAV and Associated Aortopathy in Children 
• BAV Family Screening and Genetics 
• BAV Surgical Guidelines for Aortopathy